DataWell at least CR data is inching higher and higher every 3 months. 40% 15 months CR is pretty much what I predicted a over year ago ( 40-45%) . With some patients getting a 3rd treatment, we may get closer to 45-50% IMHO. Definitely solid for a 1-2 treatment option rather than the 20-30 for the competition for roughly the same. However given that a 1 treatment yields long term efficacy Vs many more treatments to maintain efficacy is what should lead Ruvidar to become the next Gold Standard.IMHO